menu
    • menu
    [{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Axcelead","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Superluminal Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Superluminal Medicines \/ Superluminal Medicines"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Superluminal Medicines","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Superluminal Medicines","amount2":1.3,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Superluminal Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Superluminal Medicines \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Superluminal Medicines \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Superluminal Medicines

    Menu

    Superluminal Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,300.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly Signs $1.3 billion Deal with Superluminal to Discover Obesity Medicines using AI

                            Details : Through the collaboration, Superluminal will apply its platform to discover and optimize small molecule therapeutics for undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 14, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,300.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Superluminal Advances Selective MC4R Agonist To IND Studies For Obesity

                            Details : Superluminal's compound is an orally administered, highly selective, biased MC4R agonist initially targeting rare genetic forms of obesity and hypothalamic obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Axcelead

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Axcelead and Superluminal to Collaborate on Drug Discovery Targeting Molecular Mechanisms

                            Details : The collaboration aims to accelerate the discovery and development of innovative small-molecule therapeutics by jointly addressing multiple defined molecular targets with high unmet medical needs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 23, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Axcelead

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Superluminal Medicines Closes $120 Million Series A Round

                            Details : The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value GPCR targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed

                            Superluminal Medicines

                            U.S.A arrow
                            World Dairy Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : RA Capital Management

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of ...

                            Details : The funding will be used to progress Superluminal’s pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor (GPCR) targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : RA Capital Management

                            Deal Size : $33.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth